Jose Luis
Alonso Romero
Asociado Ciencias de la Salud
Hospital Vall d'Hebron
Barcelona, EspañaHospital Vall d'Hebron-ko ikertzaileekin lankidetzan egindako argitalpenak (4)
2024
2022
2021
-
Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial
European Journal of Cancer, Vol. 148, pp. 382-394
-
Pembrolizumab plus gemcitabine in the subset of triple-negative advanced breast cancer patients in the geicam/2015-04 (Pangea-breast) study
Cancers, Vol. 13, Núm. 21